Compare · ARVN vs CCCC
ARVN vs CCCC
Side-by-side comparison of Arvinas Inc. (ARVN) and C4 Therapeutics Inc. (CCCC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ARVN focuses on Biotechnology: Pharmaceutical Preparations, while CCCC focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- ARVN is the larger of the two at $423.0M, about 1.3x CCCC ($325.7M).
- ARVN has been more active in the news (9 items in the past 4 weeks vs 7 for CCCC).
- ARVN has more recent analyst coverage (25 ratings vs 24 for CCCC).
- Company
- Arvinas Inc.
- C4 Therapeutics Inc.
- Price
- -
- -
- Market cap
- $423.0M
- $325.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2020
- News (4w)
- 9
- 7
- Recent ratings
- 25
- 24
Arvinas Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.
C4 Therapeutics Inc.
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Latest ARVN
- GeneDx Announces Leadership Transition
- SEC Form EFFECT filed by Arvinas Inc.
- Arvinas to Present at Jefferies Global Healthcare Conference
- VP, Chief Accounting Officer Loomis David K sold $1,475 worth of shares (232 units at $6.36), decreasing direct ownership by 0.58% to 39,961 units (SEC Form 4) (withholding tax)
- Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
- SEC Form S-3 filed by Arvinas Inc.
- SEC Form 10-Q filed by Arvinas Inc.
- Arvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
Latest CCCC
- Amendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.
- Chief Financial Officer Adams Kendra sold $122,487 worth of shares (45,173 units at $2.71) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 337,150 units (SEC Form 4)
- SEC Form 10-Q filed by C4 Therapeutics Inc.
- C4 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- C4 Therapeutics to Participate in Upcoming November Investor Conferences
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
- Lake Street initiated coverage on C4 Therapeutics with a new price target
- Insmed Appoints Two New Directors to Its Board